leisure time -WSS

leisure time

author：explore 2025-10-01 06:01:17 - browse：3663

Kara Coluccio, a managing partner at Perspective Group poses for a portrait. -- health coverage from STAT — Kara Coluccio, a managing partner at Perspective Group, says the job market for biotech executives has gotten much tighter. Jessica Rinaldi/Globe Staff

When Crystal Shih Byers left her job at Novartis in 2020, she was excited to make the leap into a smaller startup.

Byers had spent almost nine years at Novartis, most recently helping lead a group that worked on gene therapy. But pharmaceutical companies are large and complex, and she craved more immediate impact. “I was looking for a place where I could be in the room,” she says. She wanted more autonomy, and to feel like her work would reach patients sooner.

At the time, biotech startups were rolling in cash and seeking to capture some of the magic that had fueled Moderna’s meteoric rise. They handed out lots of logo-embossed swag. “Investors were putting a lot of money into stupid science,” Byers says. “There were a lot of companies that lasted for a lot longer than I thought they would on very little data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： WATCH: Why do fingernails fall off when they're damaged?

WSS

Death of patient in Alzheimer’s trial raises question of possible risks

Biotech stock slump in 2023: awaiting the turnaround

Ukraine and a new approach to mental health in war

The strategy behind pharma's lawsuits over drug pricing reform

Drug for rare kidney disease narrowly misses mark in clinical trial

Senate HELP committee spars over health care workforce policies

leisure time

leisure time

entertainment

Medicare details structure of new drug price negotiation program

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Dobbs anniversary: the lost opportunity of abortion as health care

Weight bias in eating disorder treatment complicated by new weight loss drugs

Medical records are filled with copy

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Peter Hotez and the public health issue of online harassment

Why are elite athletes different? Take a look at their microbes

Cancer drug shortages should be causing more outrage

Second xenotransplant done with gene

hotspot

EpiPen alternative approval delay highlights citizen petition issue

Medical student insurance fails on mental health care coverage

Paxlovid study fails to answer questions over benefit for broader groups

Weight bias in eating disorder treatment complicated by new weight loss drugs

Disclosing genetic information: not as worrisome as once feared

Why are elite athletes different? Take a look at their microbes

focus

explore

explore

knowledge